The levels of PUFA and peroxidation improve with treatment for PE in CF.

<p>PUFA concentrations were measured in blood plasma of healthy controls (HC, <i>white circles</i>) and CF patients (<i>black circles</i>) at stable disease (Bsl), at PE onset (Day 1), throughout PE treatment (Days 7, 14 and 21) and post treatment (Day 42). A) AA levels decreased during PE treatment and were significantly different from Bsl values at Day 21 (p<0.05). All PE time points including Bsl were significantly different from HC, except on Day 21 where there was no longer a difference with HC. B) DHA levels improved with PE treatment and were significantly increased from Bsl values at Day 21 (p<0.05). All PE time points including Bsl were significantly different from HC. C) Overall, the AA/DHA ratio was significantly decreased from Bsl values on Day 21 (p<0.05). All PE time points including Bsl were significantly different from HC, except on Day 21 where there was no difference with HC. D) MDA levels improved with treatment however no statistical difference was detected from Bsl. All PE time points including Bsl were significantly different from HC, except on Day 21 where there was no difference with HC. Solid lines indicate the means of the groups. Dotted lines indicate the HC mean and grey shadowing illustrates the min-max range for HC values. * represents significant difference from Bsl group using the Bonferroni post-test after ANOVA. † indicates significant difference from HC group using the Bonferroni post-test after ANOVA. Significance set as p<0.05. HC n = 10, CF n = 8–13.